DPP4 inhibition impairs senohemostasis to improve plaque stability in atherosclerotic mice
Open accessThe DOI matches its Crossref record; 84 of the 86 references it cites were found in a registry or an index.
Abstract
Senescent vascular smooth muscle cells (VSMCs) accumulate in the vasculature with age and tissue damage and secrete factors that promote atherosclerotic plaque vulnerability and disease. Here, we report increased levels and activity of dipeptidyl peptidase 4 (DPP4), a serine protease, in senescent VSMCs. Analysis of the conditioned media from senescent VSMCs revealed a unique senescence-associated secretory phenotype (SASP) signature comprising many complement and coagulation factors; silencing or inhibiting DPP4 reduced these factors and increased cell death. Serum samples from persons with high risk for cardiovascular disease contained high levels of DPP4-regulated complement and coagulation factors. Importantly, DPP4 inhibition reduced senescent cell burden and coagulation and improved plaque stability, while single-cell resolution of senescent VSMCs reflected the senomorphic and senolytic effects of DPP4 inhibition in murine atherosclerosis. We propose that DPP4-regulated factors could be exploited therapeutically to reduce senescent cell function, reverse senohemostasis, and improve vascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4 Senescent hVSMCS secrete procoagulation and complement factors that are suppressed by DPP4 inhibition. (A) Schematic depicting the experimental setup for mass spectrometry analysis of the media of proliferating and senescent hVSMCs treated with and without DPP4i. (B) Volcano plot of the proteins increased (red) and decreased (blue) in senescent hVSMCs compared with proliferating hVSMCs. Proteins in red and blue have a significance (–log10 adjusted P value [Padj]) ≥2. (C) Heatmap of the complement and coagulation proteins in each CoCl2 and Doxo replicate (n = 3) compared with the mean of the proliferating control for each protein. (D) Top 10 pathways enriched using BioPlanet pathway analysis ranked by combined score in senescent hVSMCs. (E) Reactome pathway analysis as ranked by combined score representative of the top elevated proteins in senescent hVSMCs. (F) STRING functional protein association network analysis to determine protein interactions among the top elevated proteins in senescent hVSMCs. (G) Volcano plot of proteins increased (red) and decreased (blue) after DPP4i treatment of senescent hVSMCs. Proteins in red and blue have a significance (–log10 Padj) ≥ 1. (H) Heatmap of complement and coagulation proteins in senescent hVSMCs (mean of CoCl2 and Doxo replicates, n = 3) compared with senescent hVSMCs treated with DPP4i (mean of CoCl2 and Doxo replicates). (I) Schematic depiction of senescence induction in hVSMCs causing increased complement and coagulation protein secretion, which is attenuated by DPP4i treatment as determined by mass spectrometry of secreted proteins in the media.](https://figures.cochat.ai/paper-figures/18e4172058814f2ca38f15ba11034aaa/dpp4-inhibition-impairs-senohemostasis-to-improve-plaque-stability-in-figure-4.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition, SASP-associated complement and coagulation signaling pathways were recently linked to senescence, particularly in vascular cells, for which they are critical for cell survival20,21.”
From Single-cell and spatial transcriptomics map senescent vascular cells in arterial remodeling during atherosclerosis in mice (2025) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated analysis of multimodal single-cell data
Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W. M., Zheng, S., Butler, A., Lee, M. J., Wilk, A. J., Darby, C., Zagar, M., et al. (2020) · doi:10.1101/2020.10.12.335331 · Cited by 15,508
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206 · cited 1×
“Senescent cells also display a senescence-associated β -galactosidase (SA– β -gal) activity (5, 6).”
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull, W., Rosenfeld, M. E., Schwartz, C. J., Wagner, W. D., & Wissler, R. W. (1995) · Circulation · doi:10.1161/01.cir.92.5.1355 · Cited by 3,533
Simultaneous epitope and transcriptome measurement in single cells
Stoeckius, M., Hafemeister, C., Stephenson, W., Houck-Loomis, B., Chattopadhyay, P. K., Swerdlow, H., Satija, R., & Smibert, P. (2017) · Nature Methods · doi:10.1038/nmeth.4380 · Cited by 3,098
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876 · cited 1×
“While senescent cells possess beneficial functions in certain contexts, such as wound healing or development, there is overwhelming evidence that the accumulation of senescent cells in age-related diseases contributes to disease development or progression (50).”
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Hallmarks of Cellular Senescence
Hernandez-Segura, A., Nehme, J., & Demaria, M. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.02.001 · Cited by 2,605 · cited 1×
“Senescent cells also display a senescence-associated β -galactosidase (SA– β -gal) activity (5, 6).”
Senolytics improve physical function and increase lifespan in old age
Xu, M., Pirtskhalava, T., Farr, J. N., Weigand, B. M., Palmer, A. K., Weivoda, M. M., Inman, C. L., Ogrodnik, M. B., Hachfeld, C. M., Fraser, D. G., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0092-9 · Cited by 2,287
Krtolica, A., Parrinello, S., Lockett, S., Desprez, P.-Y., & Campisi, J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211053698 · Cited by 1,730
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613
A proteomic atlas of senescence-associated secretomes for aging biomarker development
Basisty, N., Kale, A., Jeon, O. H., Kuehnemann, C., Payne, T., Rao, C., Holtz, A., Shah, S., Sharma, V., Ferrucci, L., et al. (2020) · PLOS Biology · doi:10.1371/journal.pbio.3000599 · Cited by 1,348 · cited 2×
“Serum factors such as GDF15 and SERPINE1, both biomarkers of cardiovascular disease and highly conserved SASP factors, were increased with HFD and reduced with DPP4i treatment (30, 65, 66).”
Self-citationCellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338 · cited 1×
“To begin to assess the connection between senescence and DPP4 in hVSMCs, we induced hVSMC senescence using 2 different paradigms: treatment for 7 days with CoCl 2 , a hypoxia mimetic, or with Doxo, a chemo-therapeutic drug that induces DNA damage (20, 21).”
Senescent intimal foam cells are deleterious at all stages of atherosclerosis
Childs, B. G., Baker, D. J., Wijshake, T., Conover, C. A., Campisi, J., & van Deursen, J. M. (2016) · Science · doi:10.1126/science.aaf6659 · Cited by 1,195 · cited 2×
“…data show that DPP4i reduces circulating SASP coagulation factors SER-PINE1 and GDF15, necrotic core thickness and area, and the percentage of senescent cells harboring coagulation factors (p21-and FX-positive cells) around the necrotic core, all of which contribute to plaque vulnerability (37–40).”
Lamin B1 loss is a senescence-associated biomarker
Freund, A., Laberge, R.-M., Demaria, M., & Campisi, J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-10-0884 · Cited by 1,046
Roos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., Hagler, M., Jurk, D., Smith, L. A., Casaclang‐Verzosa, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12458 · Cited by 738 · cited 1×
“In mouse models of atherosclerosis, selective removal of p16-expressing senescent cells or senolytic treatments improved plaque burden in the aorta, suggesting that senescent cells participate in key aspects of atherosclerosis (40, 52–54).”
Bennett, M. R., Evan, G. I., & Schwartz, S. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117917 · Cited by 703 · cited 1×
“Previous research has shown that cellular senescence is associated with the development and progression of atherosclerosis (4).”
Astrocyte Senescence as a Component of Alzheimer’s Disease
Bhat, R., Crowe, E. P., Bitto, A., Moh, M., Katsetos, C. D., Garcia, F. U., Johnson, F. B., Trojanowski, J. Q., Sell, C., & Torres, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045069 · Cited by 586 · cited 1×
“Although senescent cells possess the ability to be both beneficial and harmful depending on the biological situation, there is little doubt that the accrual of senescent cells in older human tissues is detrimental and contributes to pathologies associated with aging (7–9).”
Interaction Between the Coagulation and Complement System
Amara, U., Rittirsch, D., Flierl, M., Bruckner, U., Klos, A., Gebhard, F., Lambris, J. D., & Huber-Lang, M. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78952-1_6 · Cited by 471
Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
Deacon, C. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00080 · Cited by 428 · cited 2×
“The role of DPP4 in metabolic and age-related diseases originated with the discovery that this exopeptidase selectively cleaves N-terminal dipeptides, inactivating GLP-1 and thereby restoring glucose homeostasis and improving type 2 diabetes (18, 19).”
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system
Klemann, C., Wagner, L., Stephan, M., & von Hörsten, S. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12781 · Cited by 425 · cited 2×
“To identify the mechanisms by which DPP4 expression levels increased in senescent hVSMCs, we focused on transcription, based on earlier studies of DPP4 production (11, 22).”
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421 · cited 1×
“While the effect of DPP4 on VSMCs is not characterized, DPP4 inhibitors, known as gliptins , are clinically used to treat diabetes (12).”
Shah, Z., Kampfrath, T., Deiuliis, J. A., Zhong, J., Pineda, C., Ying, Z., Xu, X., Lu, B., Moffatt-Bruce, S., Durairaj, R., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.041418 · Cited by 377 · cited 1×
“These results confirm a general antiinflammatory effect previously observed in atherosclerotic mice treated with DPP4i (46). sition of cells in the aorta as a result of DPP4 inhibition using single-cell RNA sequencing (scRNA-Seq) and DPP4 cellular indexing of transcriptomes and epitopes by…”
Vascular Smooth Muscle Cell Senescence Promotes Atherosclerosis and Features of Plaque Vulnerability
Wang, J., Uryga, A. K., Reinhold, J., Figg, N., Baker, L., Finigan, A., Gray, K., Kumar, S., Clarke, M., & Bennett, M. (2015) · Circulation · doi:10.1161/circulationaha.115.016457 · Cited by 349 · cited 2×
“Impor-tantly, VSMCs cultured from atherosclerotic plaques display a myriad of these senescence traits; thus, further research on senescent VSMCs in atherosclerosis is crucial to our understanding of the progression and treatment of this age-associated disease (10).”
Tissue specificity of senescent cell accumulation during physiologic and accelerated aging of mice
Yousefzadeh, M. J., Zhao, J., Bukata, C., Wade, E. A., McGowan, S. J., Angelini, L. A., Bank, M. P., Gurkar, A. U., McGuckian, C. A., Calubag, M. F., et al. (2020) · Aging Cell · doi:10.1111/acel.13094 · Cited by 331
Kalluri, A. S., Vellarikkal, S. K., Edelman, E. R., Nguyen, L., Subramanian, A., Ellinor, P. T., Regev, A., Kathiresan, S., & Gupta, R. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038362 · Cited by 330 · cited 1×
“We identified 11 cell types defined by 21 clusters of aortic cells using cell type–specific markers for all major cell types as defined in the literature (42–45) (Figure 8A, Supplemental Figure 7 and Supplemental Figure 8, A and B).”
Coronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 320 · cited 1×
“Among them, aging is one of the most important factors, increasing the prevalence, incidence, and mortality associated with atherosclerosis (1, 2).”
Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance
Ghorpade, D. S., Ozcan, L., Zheng, Z., Nicoloro, S. M., Shen, Y., Chen, E., Blüher, M., Czech, M. P., & Tabas, I. (2018) · Nature · doi:10.1038/nature26138 · Cited by 292 · cited 1×
“Sub-sequently, DPP4 was implicated in alleviating metabolism-related diseases such as obesity, chronic liver disease, and atherosclerosis (55–58).”
Gardner, S. E., Humphry, M., Bennett, M. R., & Clarke, M. C. H. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.305896 · Cited by 285 · cited 1×
“The cap of the plaque consists of a layer of vascular smooth muscle cells (VSMCs) that have dedifferentiated into synthetic, noncontractile cells that typically proliferate and migrate, but also a small population of senescent, inflammatory VSMCs (3).”
Matsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273
Identification of senescent cell surface targetable protein DPP4
Kim, K. M., Noh, J. H., Bodogai, M., Martindale, J. L., Yang, X., Indig, F. E., Basu, S. K., Ohnuma, K., Morimoto, C., Johnson, P. F., et al. (2017) · Genes & Development · doi:10.1101/gad.302570.117 · Cited by 270 · cited 4×
“To identify the mechanisms by which DPP4 expression levels increased in senescent hVSMCs, we focused on transcription, based on earlier studies of DPP4 production (11, 22).”
InfluentialSelf-citationProinflammatory Profile Within the Grossly Normal Aged Human Aortic Wall
Wang, M., Zhang, J., Jiang, L.-Q., Spinetti, G., Pintus, G., Monticone, R., Kolodgie, F. D., Virmani, R., & Lakatta, E. G. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089409 · Cited by 268
Self-citationMatrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability
Olejarz, W., Łacheta, D., & Kubiak-Tomaszewska, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113946 · Cited by 258
Plaque Rupture in Humans and Mice
Schwartz, S. M., Galis, Z. S., Rosenfeld, M. E., & Falk, E. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000261709.34878.20 · Cited by 255
Ohayon, J., Finet, G., Gharib, A. M., Herzka, D. A., Tracqui, P., Heroux, J., Rioufol, G., Kotys, M. S., Elagha, A., & Pettigrew, R. I. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00005.2008 · Cited by 243
Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions.
Li, Z., Li, L., Zielke, H. R., Cheng, L., Xiao, R., Crow, M. T., Stetler‐Stevenson, W. G., Froehlich, J. P., & Lakatta, E. G. (1996) · Europe PMC (PubMed Central) · Cited by 243
Self-citationAdipose Dipeptidyl Peptidase-4 and Obesity
Sell, H., Blüher, M., Klöting, N., Schlich, R., Willems, M., Ruppe, F., Knoefel, W. T., Dietrich, A., Fielding, B. A., Arner, P., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0496 · Cited by 218
Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
Eisert, W. G., Hauel, N., Stangier, J., Wienen, W., Clemens, A., & van Ryn, J. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.203604 · Cited by 216 · cited 1×
“We tested this possibility by incubating proliferating and senescent hVSMCs with dabigatran (Dab), a reversible and selective thrombin inhibitor (35).”
Guide for protein fold change and p -value calculation for non-experts in proteomics
Aguilan, J. T., Kulej, K., & Sidoli, S. (2020) · Molecular Omics · doi:10.1039/d0mo00087f · Cited by 204
Self-citationVascular smooth muscle cell senescence in atherosclerosis
GORENNE, I., KAVURMA, M., SCOTT, S., & BENNETT, M. (2006) · Cardiovascular Research · doi:10.1016/j.cardiores.2006.06.004 · Cited by 196 · cited 1×
“Given that DPP4 levels and activity increase with hVSMC senescence, we asked whether DPP4 is elevated in atherosclerosis, a disease in which senescent VSMCs have been implicated (24).”
Senotherapeutics for healthy ageing
Niedernhofer, L. J., & Robbins, P. D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.44 · Cited by 190 · cited 1×
“While the search for successful senolytic drugs continues, combination therapies that include senolytics and senomorphics have been suggested; it is possible that DPP4 inhibitors could be used in a similar manner (71).”
Association Between Aging of the US Population and Heart Disease Mortality From 2011 to 2017
Sidney, S., Go, A. S., Jaffe, M. G., Solomon, M. D., Ambrosy, A. P., & Rana, J. S. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.4187 · Cited by 176
Ervinna, N., Mita, T., Yasunari, E., Azuma, K., Tanaka, R., Fujimura, S., Sukmawati, D., Nomiyama, T., Kanazawa, A., Kawamori, R., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1855 · Cited by 167
Increased Plasminogen Activator Inhibitor-1 and Vasculopathy: A Reconcilable Paradox
Sobel, B. E. (1999) · Circulation · doi:10.1161/01.cir.99.19.2496 · Cited by 159 · cited 1×
“…data show that DPP4i reduces circulating SASP coagulation factors SER-PINE1 and GDF15, necrotic core thickness and area, and the percentage of senescent cells harboring coagulation factors (p21-and FX-positive cells) around the necrotic core, all of which contribute to plaque vulnerability (37–40).”
Wronkowitz, N., Görgens, S. W., Romacho, T., Villalobos, L. A., Sánchez‐Ferrer, C. F., Peiró, C., Sell, H., & Eckel, J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.004 · Cited by 159 · cited 1×
“…such that these relatively small beneficial effects may not translate well to humans; at the same time, the proinflammatory effects of DPP4 may be elicited at an early stage that promotes disease development, but may be less influential if treatment is administered at later stages (68, 69).”
Ta, N. N., Schuyler, C. A., Li, Y., Lopes-Virella, M. F., & Huang, Y. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31821e5626 · Cited by 156 · cited 3×
“Importantly, in some studies, the positive effects of these drugs are completely independent of DPP4’s canonical role in glucose metabolism (13), highlighting the need to explore other mechanisms by which DPP4 functions in atherosclerotic vascular diseases.”
Speidl, W. S., Exner, M., Amighi, J., Kastl, S., Zorn, G., Maurer, G., Wagner, O. F., Huber, K., Minar, E., Wojta, J., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi339 · Cited by 153
Ou, X., O’Leary, H. A., & Broxmeyer, H. E. (2013) · Blood · doi:10.1182/blood-2013-02-487470 · Cited by 146 · cited 2×
“Of the potential DPP4 targets, we observed no change in CCL26, increased secretion of IL-1 α and IL-1 β , which was not statistically significant, and increased secretion of LTF and TF by senescent VSMCs; however, TF was unaffected by DPP4i treat-ment (36).”
SILAC Analysis Reveals Increased Secretion of Hemostasis-Related Factors by Senescent Cells
Wiley, C. D., Liu, S., Limbad, C., Zawadzka, A. M., Beck, J., Demaria, M., Artwood, R., Alimirah, F., Lopez-Dominguez, J.-A., Kuehnemann, C., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.049 · Cited by 137 · cited 2×
“A previous study identified increased hemostasis factors in the SASP of senescent fibroblasts (31), but these factors had not been validated in other paradigms of senescence.”
Poblocka, M., Bassey, A. L., Smith, V. M., Falcicchio, M., Manso, A. S., Althubiti, M., Sheng, X., Kyle, A., Barber, R., Frigerio, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99852-2 · Cited by 137 · cited 1×
“Importantly, both Cd9 mRNA (cluster 4) and B2m mRNA (cluster 5) were associated with senescence, underscoring the heterogeneity of senescent cells even within a single cell type such as VSMCs (48, 49).”
Kenawy, H. I., Boral, I., & Bevington, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00215 · Cited by 136 · cited 1×
“A majority of the proteins altered by DPP4i treatment are cleaved and activated throughout the complement or coagulation cascade, and these two pathways often cross communicate to activate or terminate one another (32).”
Miyazaki, M. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.707 · Cited by 134
Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease
Song, C., Burgess, S., Eicher, J. D., CHARGE Consortium Hemostatic Factor Working Group, ICBP Consortium, O'Donnell, C. J., Johnson, A. D., Huang, J., Sabater‐Lleal, M., Asselbergs, F. W., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004918 · Cited by 133 · cited 1×
“Serum factors such as GDF15 and SERPINE1, both biomarkers of cardiovascular disease and highly conserved SASP factors, were increased with HFD and reduced with DPP4i treatment (30, 65, 66).”
Self-citationDipeptidyl peptidase IV (DDP IV) in NASH patients
Balaban, Y. H., Korkusuz, P., Simsek, H., Gokcan, H., Gedikoglu, G., Pinar, A., Hascelik, G., Asan, E., Hamaloglu, E., & Tatar, G. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31905-2 · Cited by 125 · cited 1×
“Sub-sequently, DPP4 was implicated in alleviating metabolism-related diseases such as obesity, chronic liver disease, and atherosclerosis (55–58).”
Roles of Growth Differentiation Factor 15 in Atherosclerosis and Coronary Artery Disease
Wang, J., Wei, L., Yang, X., & Zhong, J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012826 · Cited by 124
Zeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122 · cited 1×
“…such that these relatively small beneficial effects may not translate well to humans; at the same time, the proinflammatory effects of DPP4 may be elicited at an early stage that promotes disease development, but may be less influential if treatment is administered at later stages (68, 69).”
Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94 · cited 2×
“The role of DPP4 in metabolic and age-related diseases originated with the discovery that this exopeptidase selectively cleaves N-terminal dipeptides, inactivating GLP-1 and thereby restoring glucose homeostasis and improving type 2 diabetes (18, 19).”
Böhm, S. K., Gum, J. R., Erickson, R. H., Hicks, J. W., & Kim, Y. S. (1995) · Biochemical Journal · doi:10.1042/bj3110835 · Cited by 89 · cited 1×
“Consensus sequences for transcription factors (TFs) NF-κ B, SP1, EGFR, and AP-1 were previously found in the DPP4 promoter (23).”
Efficacy and limitations of senolysis in atherosclerosis
Garrido, A. M., Kaistha, A., Uryga, A. K., Oc, S., Foote, K., Shah, A., Finigan, A., Figg, N., Dobnikar, L., Jørgensen, H., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab208 · Cited by 83
Chang, L., Noseda, M., Higginson, M., Ly, M., Patenaude, A., Fuller, M., Kyle, A. H., Minchinton, A. I., Puri, M. C., Dumont, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118512109 · Cited by 77 · cited 1×
“DPP4-positive VSMCs were identified as TER-119 – CD45 – CD31 – CD26 + (73, 74) and sorted directly into TRIzol LS Reagent using FACS Aria FUSION (BD Bioscience) for analysis. hVSMC mass spectrometry and proteomics . hVSMCs were seeded in T75 flasks and treated with DMSO, CoCl 2 , or Doxo as well as…”
CD9 induces cellular senescence and aggravates atherosclerotic plaque formation
Cho, J. H., Kim, E.-C., Son, Y., Lee, D.-W., Park, Y. S., Choi, J. H., Cho, K., Kwon, K., & Kim, J.-R. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-0537-9 · Cited by 77 · cited 1×
“Importantly, both Cd9 mRNA (cluster 4) and B2m mRNA (cluster 5) were associated with senescence, underscoring the heterogeneity of senescent cells even within a single cell type such as VSMCs (48, 49).”
Early SRC activation skews cell fate from apoptosis to senescence
Anerillas, C., Herman, A. B., Rossi, M., Munk, R., Lehrmann, E., Martindale, J. L., Cui, C.-Y., Abdelmohsen, K., De, S., & Gorospe, M. (2022) · Science Advances · doi:10.1126/sciadv.abm0756 · Cited by 71 · cited 1×
“Surprisingly, the levels of mRNAs encoding complement and matrix remodeling factors (C2, C5, CFB, CFD, imaged and counted cells 48 hours after Doxo treatment, a time frame in which cell-fate decisions between senescence and apoptosis are apparent (34).”
Self-citationKan, H., Zhang, K., Mao, A., Geng, L., Gao, M., Feng, L., You, Q., & Ma, X. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00671-2 · Cited by 64
Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4
Casrouge, A., Sauer, A. V., da Silva, R. B., Tejera‐Alhambra, M., Sánchez‐Ramón, S., ICAReB, Cancrini, C., Ingersoll, M. A., Aiuti, A., & Albert, M. L. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13163 · Cited by 62 · cited 1×
“L, and Supplemental Figure 2, B and C), suggesting that DPP4 increases in atherosclerosis, conditions often associated with increased DPP4 is ubiquitously expressed in many cell types, especially T and B cells (22, 47).”
Attenuation of Experimental Atherosclerosis by Interleukin-19
Ellison, S., Gabunia, K., Kelemen, S. E., England, R. N., Scalia, R., Richards, J. M., Orr, A. W., Traylor, J. G., Rogers, T., Cornwell, W., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301521 · Cited by 58
Gabunia, K., Ellison, S. P., Kelemen, S. E., Kako, F., Cornwell, W. D., Rogers, T. J., Datta, P. K., Ouimet, M. I., Moore, K. J., & Autieri, M. V. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.12.023 · Cited by 58
Salim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2015.08.011 · Cited by 56
Posthuma, J. J., Posma, J., van Oerle, R., Leenders, P. J. A., van Gorp, R. H., Jaminon, A. M. G., Mackman, N., Heitmeier, S., Schurgers, L. J., Cate, H. T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-40602-w · Cited by 55 · cited 2×
“Recently, coagulation factor IX was implicated as a regulator of senescence in cancer cells and inhibition of coagulation factor Xa induced plaque regression and increased plaque stability (60, 61).”
Kadoglou, N. P. E., Moustardas, P., Kapelouzou, A., Katsimpoulas, M., Giagini, A. T., Dede, E., Kostomitsopoulos, N. G., Karayannacos, P., Kostakis, A. I., & Liapis, C. D. (2013) · European Journal of Histochemistry · doi:10.4081/ejh.2013.e3 · Cited by 54
Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX‑1 in apoE‑/‑ mice
Li, Y., Jia, Q., Cao, H., Chen, C., Xing, S., Huang, Y., & Shen, D. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9457 · Cited by 52 · cited 1×
“In mouse models of atherosclerosis, selective removal of p16-expressing senescent cells or senolytic treatments improved plaque burden in the aorta, suggesting that senescent cells participate in key aspects of atherosclerosis (40, 52–54).”
Valencia, I., Vallejo, S., Dongil, P., Romero, A., Hipólito‐Luengo, Á. S., Shamoon, L., Posada-Ayala, M., García‐Olmo, D., Carraro, R., Erusalimsky, J. D., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18477 · Cited by 51 · cited 2×
“As mentioned, recent studies have identified DPP4 on the surface of senescent cells, and soluble DPP4 was found to trigger endothelial senescence, demonstrating that DPP4 may contribute to the development of the senescent phenotype (11, 59).”
He, D., Mao, A., Zheng, C., Kan, H., Zhang, K., Zhang, Z., Feng, L., & Ma, X. (2020) · National Science Review · doi:10.1093/nsr/nwaa038 · Cited by 47 · cited 1×
“We identified 11 cell types defined by 21 clusters of aortic cells using cell type–specific markers for all major cell types as defined in the literature (42–45) (Figure 8A, Supplemental Figure 7 and Supplemental Figure 8, A and B).”
Hirano, T., Yamashita, S., Takahashi, M., Hashimoto, H., Mori, Y., & Goto, M. (2016) · Metabolism · doi:10.1016/j.metabol.2016.03.010 · Cited by 39
The regulatory role of DPP4 in atherosclerotic disease
Duan, L., Rao, X., Xia, C. Q., Rajagopalan, S., & Zhong, J. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0558-y · Cited by 39 · cited 1×
“To date, DPP4 inhibitors have not been effective in clinical studies to improve cardiovascular outcomes (67); however, many animal studies have demonstrated reduced atherosclerotic burden and inflammation in animals treated with these drugs (29).”
ApoE−/− PGC-1α−/− Mice Display Reduced IL-18 Levels and Do Not Develop Enhanced Atherosclerosis
Stein, S., Lohmann, C., Handschin, C., Stenfeldt, E., Borén, J., Lüscher, T. F., & Matter, C. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013539 · Cited by 35
Carpintero-Fernández, P., Borghesan, M., Eleftheriadou, O., Pan‐Castillo, B., Fafián‐Labora, J., Mitchell, T. P., Yuste, A., Öğrünç, M., Nightingale, T. D., Mayán, M. D., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04569-3 · Cited by 32 · cited 1×
“Recently, coagulation factor IX was implicated as a regulator of senescence in cancer cells and inhibition of coagulation factor Xa induced plaque regression and increased plaque stability (60, 61).”
Herman, A. B., Anerillas, C., Harris, S. C., Munk, R., Martindale, J. L., Yang, X., Mazan-Mamczarz, K., Zhang, Y., Heckenbach, I. J., Scheibye-Knudsen, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab538 · Cited by 31 · cited 1×
“Apoptosis was monitored by measuring caspase-3 and -7 activity using the Caspase-Glo 3/7 Assay System (Promega) as previously described (72).”
Self-citationPaez-Cortez, J. R., Krishnan, R., Arno, A., Aven, L., Ram‐Mohan, S., Patel, K. R., Lü, J., King, O. D., Ai, X., & Fine, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074469 · Cited by 28 · cited 1×
“DPP4-positive VSMCs were identified as TER-119 – CD45 – CD31 – CD26 + (73, 74) and sorted directly into TRIzol LS Reagent using FACS Aria FUSION (BD Bioscience) for analysis. hVSMC mass spectrometry and proteomics . hVSMCs were seeded in T75 flasks and treated with DMSO, CoCl 2 , or Doxo as well as…”
Lewińska, A., Adamczyk‐Grochala, J., Błoniarz, D., Horeczy, B., Żurek, S., Kurowicki, A., Wołoszczuk-Gębicka, B., Widenka, K., & Wnuk, M. (2020) · Aging · doi:10.18632/aging.103604 · Cited by 28 · cited 1×
“To begin to assess the connection between senescence and DPP4 in hVSMCs, we induced hVSMC senescence using 2 different paradigms: treatment for 7 days with CoCl 2 , a hypoxia mimetic, or with Doxo, a chemo-therapeutic drug that induces DNA damage (20, 21).”
Negishi, K., Hoshide, S., Shimpo, M., Kanegae, H., & Kario, K. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022601 · Cited by 26 · cited 1×
“Serum factors such as GDF15 and SERPINE1, both biomarkers of cardiovascular disease and highly conserved SASP factors, were increased with HFD and reduced with DPP4i treatment (30, 65, 66).”
Zhang, K., Kan, H., Mao, A., Geng, L., & Ma, X. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00704-w · Cited by 24
Singh, T. P., Vangaveti, V., & Malabu, U. H. (2015) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2015.04.005 · Cited by 19 · cited 4×
“We sought to recapitulate previous studies in which DPP4 inhibitors were effective at reducing atherosclerosis and inflammation in mice (29).”
InfluentialLiu, X., Ni, M., Ma, L., Yang, J., Wang, L., Liu, F., Dong, M., Yang, X., Zhang, M., Lu, H., et al. (2015) · Scientific Reports · doi:10.1038/srep10225 · Cited by 17 · cited 1×
“…proteins has particular relevance in vascular diseases in which thrombosis and plaque vulnerability critically increase the risk of mortality (61, 62); therefore, targeting senescent cells in the atherosclerotic niche may reduce the probability of thrombosis or plaque rupture, as previously…”
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
Hoffmann‐Petersen, I. T., Holt, C. B., Jensen, L., Hage, C., Mellbin, L., Thiel, S., Hansen, T. K., & Østergaard, J. A. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3385 · Cited by 13 · cited 1×
“A recent study found that DPP4 inhibitors directly suppressed the functional activity of the lectin complement pathway, independently of DPP4, suggesting that DPP4 inhibitors can suppress the SASP of any cell-secreting complement factors (70).”
Research works printed but not linked: 1
- Harman SM et al Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging J Clin Endocrinol Metab 2001 86 2 724 731 10.1210/jcem.86.2.7219 11158037 · DOI · Paper page
Cited by
Current senolytics: Mode of action, efficacy and limitations, and their future
Rad, A. N., & Grillari, J. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111888 · Cited by 83
Mazan-Mamczarz, K., Tsitsipatis, D., Childs, B. G., Carr, A. E., Dos Santos, C. R., Anerillas, C., Romero, B., Gregg, J. M., Henry-Smith, C., Okereke, A. N., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00889-z · Cited by 48
“In addition, SASP-associated complement and coagulation signaling pathways were recently linked to senescence, particularly in vascular cells, for which they are critical for cell survival 20,21 .”
Self-citationThe complement system in lipid-mediated pathologies
Alić, L., Dendinovic, K., & Papac-Miličević, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1511886 · Cited by 20
Mahoney, S. A., Dey, A. K., Basisty, N., & Herman, A. B. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00352.2023 · Cited by 21
Self-citationKról, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
“Additionally, DPP-4i reduced foam cell formation of macrophages isolated from T1D mice and patients [90] and mitigated inflammation [38] and plaque instability in in vivo studies [91].”
Metadata
- Authors
- Herman, A. B., Tsitsipatis, D., Anerillas, C., Mazan-Mamczarz, K., Carr, A. E., Gregg, J. M., Wang, M., Zhang, J., Michel, M., Henry-Smith, C. A., Harris, S. C., Munk, R., Martindale, J. L., Piao, Y., Fan, J., Mattison, J. A., De, S., Abdelmohsen, K., Maul, R. W., Tanaka, T., Moore, A. Z., DeMouth, M. E., Sidoli, S., Ferrucci, L., Liu, Y., de Cabo, R., Lakatta, E. G., & Gorospe, M.
- Affiliations
- National Institutes of Health (US)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Herman, Allison B.
- ORCID
- Herman, Allison B.
- Tsitsipatis, Dimitrios
- Anerillas, Carlos
- Mazan-Mamczarz, Krystyna
- Carr, Angelica E.
- Gregg, Jordan M.
- Wang, Mingyi
- Munk, Rachel
- Martindale, Jennifer L.
- Fan, Jinshui
- Mattison, Julie A.
- De, Supriyo
- Abdelmohsen, Kotb
- Maul, Robert W.
- Tanaka, Toshiko
- Moore, Ann Zenobia
- DeMouth, Megan E.
- Sidoli, Simone
- Ferrucci, Luigi
- Liu, Yie
- de Cabo, Rafael
- Lakatta, Edward G.
- Gorospe, Myriam
- Venue
- Journal of Clinical Investigation
- Published
- 2023-06-15
- Volume
- 133
- Issue
- 12
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC10266795
- OpenAlex
- W4366983099
- Cited by
- 50
- References
- 86
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 8 · 2023: 7
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (1s10od030286-01)
- National Institute on Aging
- National Cancer Institute (P30CA013330)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Keywords
- dipeptidyl peptidase IV, DPP-4 inhibition, vascular smooth muscle cell senescence, senescence-associated secretory phenotype, atherosclerotic plaque stability, complement proteins, coagulation factors, senolytic therapy, cardiovascular risk
- MeSH terms
- Animals, Muscle, Smooth, Vascular, Cellular Senescence, Dipeptidyl Peptidase 4, Atherosclerosis, Mice, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.